Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved publishing date : 2021 - 12 - 09 save search
iAnthus Provides Update on the Florida Regulatory Approval for the Recapitalization Transaction Change of Ownership
Published: 2021-12-09 (Crawled : 23:00) - prnewswire.com
ITHUF | $0.0177 32K
|
Process Industries
|
| O: -2.61%
H: 9.15%
C: 5.28%
approval
Methode Electronics’ Board Approves Dividend
Published: 2021-12-09 (Crawled : 22:00) - globenewswire.com
MEI | $12.2 1.16% 86K
|
Electronic Technology
|
| O: 0.87%
H: 0.74%
C: -0.68%
electronics
American Outdoor Brands Board of Directors Approves $15 Million Share Repurchase Program
Published: 2021-12-09 (Crawled : 21:00) - prnewswire.com
AOUT | $8.48 1.92% 1.2K
|
Consumer Durables
|
| O: -16.27%
H: 7.78%
C: 3.47%
brands
DTE Energy receives approval from Michigan Public Service Commission to further modernize natural gas infrastructure
Published: 2021-12-09 (Crawled : 21:00) - globenewswire.com
DTE | News | $110.19 0.06% 150K
|
Utilities
|
| O: 0.51%
H: 0.6%
C: 0.35%
natural gas approval energy
VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.28%
H: 1.84%
C: 1.59%
fda eye drop presbyopia
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
HRTX M | $2.74 -2.14% 860K
|
Health Technology
|
| O: 0.72%
H: 18.55%
C: 10.58%
zynrelef fda expansion fda approval approval therapeutics
FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue
Published: 2021-12-09 (Crawled : 14:00) - biospace.com/
TMO | News | $568.365 -1.08% 680K
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: 0.0%
diagnostic fda lung cancer cancer
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM
Published: 2021-12-09 (Crawled : 13:00) - biospace.com/
CYTK | $66.21 0.98% 150K
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
treatment fda cardio granted therapy results breakthrough therapy designation
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.